An exploratory imaging substudy of a 32-week randomised trial finds semaglutide and empagliflozin each lower cortical apparent diffusion coefficient and reduce total kidney volume in type 2 diabetes. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
PIONEER 11 found that oral semaglutide monotherapy lowered HbA1c at all doses versus placebo in drug-naive, predominantly Chinese adults with type 2 diabetes, with weight reduction confined to the 7 mg and 14 mg doses. PICO summary and expert commentary.
Prespecified FLOW secondary analysis testing whether semaglutide’s kidney and cardiovascular benefit differs by baseline SGLT2 inhibitor use in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
Pre-specified FLOW subgroup analysis of semaglutide for kidney outcomes in type 2 diabetes and chronic kidney disease, by baseline SGLT2 inhibitor use. PICO summary and expert commentary.
In the FLOW trial, once-weekly semaglutide 1.0 mg lowered the risk of major kidney disease events and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg)…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40…
A clinical guideline update on the prevention or delay of diabetes and associated comorbidities was published in January 2025 by the American Diabetes Association (ADA) Professional Practice Committee. These guidelines, published in Diabetes Care (2025;48(Suppl. 1):S50–S58).
Summary: In 178 adults with T2D (HbA1c 7.0-10.5%) on stable metformin, once-weekly semaglutide (0.25-1.0 mg) for 52 weeks produced numerically…